117 related articles for article (PubMed ID: 34239147)
1. An NP-led pilot telehealth programme to facilitate guideline-directed medical therapy for heart failure with reduced ejection fraction during the COVID-19 pandemic.
McLachlan A; Aldridge C; Morgan M; Lund M; Gabriel R; Malez V
N Z Med J; 2021 Jul; 134(1538):77-88. PubMed ID: 34239147
[TBL] [Abstract][Full Text] [Related]
2. Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
Desai AS; Maclean T; Blood AJ; Bosque-Hamilton J; Dunning J; Fischer C; Fera L; Smith KV; Wagholikar K; Zelle D; Gaziano T; Plutzky J; Scirica B; MacRae CA
JAMA Cardiol; 2020 Dec; 5(12):1430-1434. PubMed ID: 32936209
[TBL] [Abstract][Full Text] [Related]
3. Telephone-Based Guideline-Directed Medical Therapy Optimization in Navajo Nation: The Hózhó Randomized Clinical Trial.
Eberly LA; Tennison A; Mays D; Hsu CY; Yang CT; Benally E; Beyuka H; Feliciano B; Norman CJ; Brueckner MY; Bowannie C; Schwartz DR; Lindsey E; Friedman S; Ketner E; Detsoi-Smiley P; Shyr Y; Shin S; Merino M
JAMA Intern Med; 2024 Jun; 184(6):681-690. PubMed ID: 38583185
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
Blood AJ; Fischer CM; Fera LE; MacLean TE; Smith KV; Dunning JR; Bosque-Hamilton JW; Aronson SJ; Gaziano TA; MacRae CA; Matta LS; Mercurio-Pinto AA; Murphy SN; Scirica BM; Wagholikar K; Desai AS
Clin Cardiol; 2020 Jan; 43(1):4-13. PubMed ID: 31725920
[TBL] [Abstract][Full Text] [Related]
5. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
[TBL] [Abstract][Full Text] [Related]
6. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
7. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
8. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
[TBL] [Abstract][Full Text] [Related]
10. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.
Daubert MA; Adams K; Yow E; Barnhart HX; Douglas PS; Rimmer S; Norris C; Cooper L; Leifer E; Desvigne-Nickens P; Anstrom K; Fiuzat M; Ezekowitz J; Mark DB; O'Connor CM; Januzzi J; Felker GM
JACC Heart Fail; 2019 Feb; 7(2):158-168. PubMed ID: 30611722
[TBL] [Abstract][Full Text] [Related]
11. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
12. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, Presentation, and Outcome of Heart Failure with Preserved Ejection Fraction among Patients Presenting with Undifferentiated Dyspnoea to the Emergency Room: A 10-year Analysis from a Tertiary Centre.
Ruan W; Lim SH; Ding ZP; Sim DK; Gao F; Gunasegaran K; Kwok BW; Tan RS
Ann Acad Med Singap; 2016 Jan; 45(1):18-26. PubMed ID: 27118225
[TBL] [Abstract][Full Text] [Related]
14. Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study.
Kurgansky KE; Schubert P; Parker R; Djousse L; Riebman JB; Gagnon DR; Joseph J
BMC Cardiovasc Disord; 2020 Feb; 20(1):92. PubMed ID: 32101141
[TBL] [Abstract][Full Text] [Related]
15. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.
Verma AK; Sun JL; Hernandez A; Teerlink JR; Schulte PJ; Ezekowitz J; Voors A; Starling R; Armstrong P; O'Conner CM; Mentz RJ
Clin Cardiol; 2018 Jul; 41(7):945-952. PubMed ID: 29781109
[TBL] [Abstract][Full Text] [Related]
16. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.
Givertz MM; Stevenson LW; Costanzo MR; Bourge RC; Bauman JG; Ginn G; Abraham WT;
J Am Coll Cardiol; 2017 Oct; 70(15):1875-1886. PubMed ID: 28982501
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
20. Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
Nauta JF; Hummel YM; Tromp J; Ouwerkerk W; van der Meer P; Jin X; Lam CSP; Bax JJ; Metra M; Samani NJ; Ponikowski P; Dickstein K; Anker SD; Lang CC; Ng LL; Zannad F; Filippatos GS; van Veldhuisen DJ; van Melle JP; Voors AA
Eur J Heart Fail; 2020 Jul; 22(7):1147-1155. PubMed ID: 31713324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
